1. Progression-free survival was significantly greater among patients in the pembrolizumab group compared to placebo (10.0 vs. 8.1 months). 2. ...
1. The median overall survival and event-free survival were not statistically different in the pembrolizumab group as compared to the ...
1. Progression-free survival was significantly greater among patients in the pembrolizumab group compared to placebo (10.0 vs. 8.1 months). 2. ...
1. The median overall survival and event-free survival were not statistically different in the pembrolizumab group as compared to the ...
Click here to read this study in NEJM. ©2023 2 Minute Medicine, Inc. All rights reserved. No works may be ...
1. At 24 months, more participants in the pembrolizumab group were alive without an event, compared with the placebo group. ...
1. Median overall survival was greater in the pembrolizumab group compared to the control group (12.7 months vs. 10.9 months). 2. ...
1. Median overall survival was greater in the pembrolizumab group compared to the control group (12.7 months vs. 10.9 months). ...
Click here to read this study in NEJM. ©2023 2 Minute Medicine, Inc. All rights reserved. No works may be ...
1. Event-free survival at 2 years was longer in the neoadjuvant-adjuvant group vs the adjuvant-only group (72% vs 49%). 2. ...
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
